This has led to the emergence of several noninvasive scoring systems utilizing anthropometric data and easily available clinical parameters such as aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, AST‐to‐platelet ratio index (APRI), body mass index (BMI), AST/ALT ratio, diabetes (BARD) score, fibrosis‐4 (FIB‐4) score, and NAFLD fibrosis score (NFS). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.